English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The performance of randomized clinical trials provides evidence-based medical information to clinicians and impacts on day-to-day treatment decisions. Many secondary stroke prevention trials over the past 4 decades have provided much useful information concerning the efficacy or lack thereof of different therapies for reducing recurrent stroke risk. For platelet antiaggregants, placebo-controlled trials are no longer justified and comparator trials evaluating drug combinations in comparison to monotherapy are appropriate. The MATCH trial evaluated the efficacy and safety of combined clopidogrel–aspirin therapy to clopidogrel alone in high-risk patients with completed stroke or transient ischemic attack who also had 1 or more of 5 additional risk factors. The combined endpoint of ischemic stroke, myocardial infarction, vascular death, or recurrent hospitalization for an ischemic …

The MATCH Study Results in the Context of Secondary Stroke Prevention